Effectiveness of statins in acute coronary syndromes

American Journal of Cardiology

Volumn 88, Issue 4 SUPPL. 1, 2001, Pages 31-35

  Foody, JoAnne Micale ^a   Nissen, Steven E ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN;

ARTICLE; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; DRUG EFFICACY; HEART MUSCLE ISCHEMIA; HUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 0035899377     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(01)01875-6     Document Type: Article

References (41)

1. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
2. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
3. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS
4. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
5. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
6. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease
7. Lipid lowering and plaque regression: New insights into prevention of plaque disruption and clinical events in coronary disease
8. Coronary plaque disruption
9. Pathogenic mechanisms of atherosclerosis: Effect of lipid lowering on the biology of atherosclerosis
10. Single LDL apheresis improves endothelium-dependent vasodilation in hypercholesterolemic humans
11. Coronary flow reserve is impaired in young men with familial hypercholesterolemia
12. ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: Executive summary and recommendations: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients with Chronic Stable Angina)
13. The treatment gap in coronary artery disease and heart failure: Community standards and the post-discharge patient
14. Recent trends in the identification and treatment of high blood cholesterol by physicians: Progress and missed opportunities
15. Divergent reporting of coronary risk factors before coronary artery bypass surgery
16. Low incidence of assessment and modification of risk factors in acute care patients at high risk for cardiovascular events, particularly among females and the elderly
17. Improving physician compliance with a health maintenance protocol
18. Physician non-compliance with the 1993 National Cholesterol Education Program (NCEP-ATP II) Guidelines
19. Biological mechanisms for the clinical success of lipid-lowering in coronary artery disease and the use of surrogate end-points
20. Chronic inhibition of nitric oxide production accelerates neointima formation and impairs endothelial function in hypercholesterolemic rabbits
21. Role of endothelial dysfunction in coronary artery disease and implications for therapy
22. Modulation of coronary vasomotor tone in humans
23. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion
24. Effect of a single high-fat meal on endothelial function in healthy subjects
25. Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolaemic patients
26. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes: The RECIFE (Reduction of Cholesterol in Ischemia and Function of the Endothelium) trial
27. Short-term cholesterol lowering decreases size and severity of perfusion abnormalities by positron emission tomography after dipyridamole in patients with coronary artery disease: A potential noninvasive marker of healing coronary endothelium
28. Effect of cholesterol reduction on myocardial ischemia in patients with coronary disease
29. Levels of soluble cell adhesion molecules in patients with dyslipidemia
30. Inhibitory effect of fluvastatin, an HMG-CoA reductase inhibitor, on the expression of adhesion molecules on human monocyte cell line
31. Relationship between mevalonate pathway and arterial myocyte proliferation: In vitro studies with inhibitors of HMG-CoA reductase
32. Effects of long-term treatment with lovastatin on the clotting system and blood platelets
33. Hyperlipidemia and coronary disease: Correction of the increased thrombogenic potential with cholesterol reduction
34. Deisgn, rationale, and baseline characteristics of the Prospective Pravastatin Pooling (PPP) project - A combined analysis of three large-scale randomized trials: Long-term Intervention with Pravastatin in Ischemic Disease (LIPID), Cholesterol and Recurrent Events (CARE), and West of Scotland Coronary Prevention Study (WOSCOPS)
35. Aggressive lipid lowering therapy compared with angioplasty in stable coronary artery disease
36. Pravastatin prevents clinical events in revascularized patients with average cholesterol concentrations
37. Time course of serum lipids and apolipoproteins after acute myocardial infarction: Modification by pravastatin
38. Short- and long-term effects of intensified versus conventional antilipidemic therapy in patients with coronary heart disease: Results from the Lipid-Coronary Artery Disease (L-CAD) Study
39. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL Study: A randomized controlled trial
40. Improved treatment of cardiovascular disease by implementation of a cardiac hospitalization atherosclerosis management program: CHAMP